Related Experiment Video
Updated: Oct 31, 2025

Author Spotlight: Exploring the Complexities of Achilles Tendon Injuries — Research and Future Directions
Published on: October 27, 2023
Achilles Tendon Thickness Assessed by X-ray Predicting a Pathogenic Mutation in Familial Hypercholesterolemia Gene
Hayato Tada1, Mika Hori2,3,4, Kota Matsuki5
1Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences.
Insights
The 2017 Japan Atherosclerosis Society (JAS) criteria for familial hypercholesterolemia (FH) may miss patients due to an outdated Achilles tendon thickness (ATT) threshold. This study suggests lower ATT cut-offs for X-ray diagnosis, improving FH identification.
Area of Science:
- Cardiology
- Genetics
- Radiology
Background:
- The 2017 Japan Atherosclerosis Society (JAS) familial hypercholesterolemia (FH) criteria use an Achilles tendon thickness (ATT) cut-off of ≥9 mm from X-ray.
- This threshold is based on outdated data and may lead to underdiagnosis in FH patients with ATT <9 mm.
Purpose of the Study:
- To determine an optimal X-ray-based Achilles tendon thickness (ATT) cut-off value for differentiating familial hypercholesterolemia (FH) from non-FH individuals using genetic diagnosis.
- To re-evaluate the diagnostic accuracy of ATT measurements in FH detection.
Main Methods:
- Genetic analysis of FH-genes (LDLR, PCSK9), serum lipid levels, and X-ray-based ATT measurements were performed on 987 individuals (486 males, 501 females).
- Receiver operating characteristic (ROC) analyses were conducted to identify the best ATT cut-off values for predicting FH pathogenic mutations.
Main Results:
- ROC analysis identified optimal ATT cut-off values of 7.6 mm for males (sensitivity/specificity 0.83/0.83) and 7.0 mm for females (sensitivity/specificity 0.86/0.85).
- Applying proposed thresholds (8.0/7.5 mm for males, 7.5/7.0 mm for females) improved sensitivity/specificity for predicting FH pathogenic mutations compared to the current 2017 JAS criteria.
Conclusions:
- The established cut-off value of 9.0 mm for Achilles tendon thickness (ATT) in the 2017 JAS FH criteria is likely too high.
- Lower ATT cut-off values derived from this study could enhance the diagnostic accuracy for familial hypercholesterolemia (FH) through X-ray imaging.
Aim:
The 2017 Japan Atherosclerosis Society (JAS) familial hypercholesterolemia (FH) criteria adopt a cut-off value of ≥ 9 mm of Achilles tendon thickness (ATT) detected by X-ray as one of the three key items. This threshold was determined based on an old data evaluating the ATT of 36 non-FH individuals that was published in 1977. Although the specificity of these clinical criteria is extremely high due to a strict threshold, there are a significant number of patients with FH whose ATT <9 mm. We aimed to determine a cut-off value of ATT detected by X-ray to differentiate FH and non-FH based on genetic diagnosis.
Methods:
The individuals (male/female=486/501) with full assessments of genetic analyses for FH-genes (LDLR and PCSK9), serum lipids, and ATT detected by X-ray at the Kanazawa University Hospital and National Cerebral and Cardiovascular Center Research Institute were included in this study. Receiver operating characteristic (ROC) analyses were conducted to determine a better cut-off value of ATT that predicts the pathogenic mutation of FH.
Results:
The ROC analyses revealed that the best cut-off values of ATT are 7.6 mm for male and 7.0 mm for female, with the sensitivities/specificities of 0.83/0.83 for male and 0.86/0.85 for female, respectively. If the thresholds of ATT of 8.0/7.5 mm and 7.5/7.0 mm were applied to the diagnosis of male/female FH, the sensitivities/specificities predicting the pathogenic mutation of FH by the 2017 JAS FH clinical criteria would be 0.82/0.90 and 0.85/0.88, respectively.
Conclusions:
These results suggest that the cut-off value of ATT detected by X-ray is obviously lower than 9.0 mm, which was adopted by the 2017 JAS FH clinical criteria.
Related Concept Videos
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Cardiomyopathy III: Hypertrophic Cardiomyopathy

